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Homozygosity or compound heterozygosity for the c.833T4C transition (p.I278T) in the cystathionine beta-
synthase (CBS) gene represents the most common cause of pyridoxine-responsive homocystinuria in Western
Eurasians. However, the frequency of the pathogenic c.833C allele, as observed in healthy newborns from
several European countries (qc.833C F 3.3   10
–3), is  20-fold higher than expected on the basis of the
observed number of symptomatic homocystinuria patients carrying this mutation (qc.833C F 0.18   10
–3),
implying clinical underascertainment. Intriguingly, the c.833C mutation is also present in combination with a
68-bp insertion, c.[833C; 844_845ins68], in a substantial proportion of chromosomes from nonhomocystinuric
individuals worldwide. We have sought to study the relationship between the pathogenic and nonpathogenic
c.833C-bearing chromosomes and to determine whether the pathogenic c.[833C;  ] chromosomes are identical-
by-descent or instead arose by recurrent mutation. Initial haplotype analysis of 780 randomly selected Czech
and sub-Saharan African wild-type chromosomes, employing 12 intragenic markers, revealed 29 distinct CBS
haplotypes, of which 10 carried the c.[833C; 844_845ins68] combination; none carried an isolated c.833C or
c.844_845ins68 mutation. Subsequent examination of 69 pathogenic c.[833C;  ] chromosomes, derived from
homocystinuria patients of predominantly European origin, disclosed three unrelated haplotypes that differed
from their wild-type counterparts by virtue of the presence of c.833C, thereby indicating that c.833T4C
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INTRODUCTION
Autosomal recessive cystathionine beta-synthase (CBS) defi-
ciency (MIM] 236200) is the most common inborn error of sulfur
metabolism and was first recognized over four decades ago [Mudd
et al., 1964]. Untreated CBS deficiency is characterized clinically
by skeletal and ocular abnormalities, as well as thromboembolism
and mental retardation. However, early treatment by administra-
tion of high doses of pyridoxine and/or by methionine restriction
combined with betaine administration has proven effective in
preventing many complications of this disease [Mudd et al., 2001].
The clinical, biochemical, and molecular aspects of CBS deficiency
have recently been reviewed in detail [Koz ˇich and Kraus, 2001;
Mudd et al., 2001].
Molecular analysis of the CBS gene in patients with homo-
cystinuria has led to the identification of some 130 different
pathogenic mutations, the majority of which are rare and private
[Kraus et al., 1999] (www.hgmd.org; www.uchsc.edu/cbs/cbsdata/
cgidata.htm). Although several mutations are frequent, only the
transition c.833T4C (p.I278T) in exon 8 of the CBS gene [Kraus
et al., 1999] has been reported to occur in virtually every studied
population of European origin (www.uchsc.edu/cbs/cbsdata/cgidata.
htm). The nonpolar Ile278 residue is highly conserved between
mammals, Neurospora sp., Anopheles gambiae, Pichia pastoris,
and several bacterial species. However, other species such as
Xenopus sp., Fugu rubripes, Drosophila melanogaster, Dictyostelium
discoides, Caenorhabditis elegans, and Saccharomyces cerevisiae
have a smaller valine residue at the analogous position, suggesting
that the enzyme may tolerate mild spatial alterations. By
contrast, the substitution of the nonpolar isoleucine by the polar
threonine is clearly unfavorable since the mutant enzyme is
inactivated [Koz ˇich and Kraus, 1992; Shan et al., 2001] as a
consequence of misfolding, loss of heme, and protein aggrega-
tion [Janos ˇı ´k et al., 2001]. Despite the detrimental impact of
the mutation on enzymatic properties, homozygosity or compound
heterozygosity for the c.833C allele is consistently associated
with a mild clinical phenotype, both in humans and in trans-
genic mice [Mudd et al., 2001; Wang et al., 2005]. More
importantly, carriership of at least one c.833C allele in CBS-
deficient patients confers clinical and biochemical responsive-
ness to vitamin B6 administration, and consequently necessitates
a less severe therapeutic regimen [Koz ˇich and Kraus, 2001;
Mudd et al., 2001].
At present, the c.833C allele would appear to be the most
common pathogenic CBS variant in Western Eurasians suffering
from CBS deficiency. Indeed, in symptomatic homocystinuric
patients, c.833C constitutes  25% of all homocystinuric alleles
(132/553 alleles as of April 2006; www.uchsc.edu/cbs/cbsdata/
cgidata.htm). Further, an unusually high prevalence of hetero-
zygotes for this variant has been observed among Danish, German,
Czech, and Norwegian newborns (i.e., 1:71, 1:67, 1:257, and
1:63, respectively) and in healthy Dutch adults (i.e., 1:250)
[Gaustadnes et al., 1999; Griffioen et al., 2005; Linnebank et al.,
2001a; Refsum et al., 2004; Sokolova ´ et al., 2001].
Only a small proportion of human chromosomes carry the
pathogenic mutation c.833C on its own (henceforth referred to
as c.[833C;  ] chromosomes), whereas a much larger proportion
contain a nonpathogenic combination of two mutations (termed
c.[833C; 844_845ins68] chromosomes). In the latter chromo-
somes, the pathogenic effect of c.833C is completely nullified by
the downstream insertion of a 68-bp duplicated portion of the
intron 7/exon 8 junction (Fig. 1C). Although this insertion creates
two intron 7 splice donor sites in close proximity, the splicing
machinery strongly favors the use of the more distal splice donor
site, thereby removing the upstream segment of exon 8 together
with the c.833C mutation while preserving the rest [Romano
et al., 2002; Sperandeo et al., 1996b; Tsai et al., 1996].
Consequently, both heterozygotes and homozygotes carrying the
nonpathogenic c.[833C; 844_845ins68] chromosomes synthesize
normal CBS mRNA molecules lacking the pathogenic r.833U4C
mutation; these individuals therefore exhibit neither biochemical
nor clinical signs of homocystinuria [Pepe et al., 1999; Tsai et al.,
1996]. The nonpathogenic c.[833C; 844_845ins68] chromosomes
are very common in sub-Saharan Africa (up to 40% of control
chromosomes), less frequent throughout Europe and America
(5–10% of control chromosomes) [Franco et al., 1998b; Pepe
et al., 1999], and comparatively rare in Asia (0.16–2.5% of control
chromosomes) [Song et al., 2001; Zhang and Dai, 2001].
The relatively high frequency of pathogenic c.[833C;  ]
chromosomes in populations of European descent could have
resulted from a number of different mechanisms, including
recurrent mutation in a mutational hotspot or gene conversion
using the common nonpathogenic c.[833C; 844_845ins68]
chromosomes as templates. In addition, positive selection
for carriers, random genetic drift or a combination of these
mechanisms could have been responsible for boosting the
population frequencies of the pathogenic c.[833C;  ] chromo-
somes to their present values. We have adopted several different
approaches in an attempt to distinguish between two competing
hypotheses, namely: 1) that the pathogenic c.[833C;  ]
chromosomes are identical-by-descent; or 2) that these chromo-
somes arose by recurrent mutation, possibly involving c.[833C;
844_845ins68] chromosomes as templates.
PATIENTSANDMETHODS
Patients
All patients in the present study suffered from homocystinuria
due to CBS deficiency, and were either homozygous or compound
heterozygous for the pathogenic c.[833C;  ] chromosomes.
Through an international cooperative effort, samples of genomic
DNA, blood or fibroblasts were obtained from a total of
54 unrelated subjects, representing 71 independent c.[833C;  ]
chromosomes. A total of 11 patients each were from the
Netherlands and Italy, nine were from Germany, six from
Denmark, five from Australia, four from the Czech Republic,
two each from Ireland and France, and one each from Poland,
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patient were of European ancestry.
Control individuals facilitating the haplotype analysis of wild-
type CBS chromosomes had previously been ascertained in two
different studies. Banked genomic DNA samples were obtained
from 200 anonymous Czech [Janos ˇı ´kova ´ et al., 2003] and 190
anonymous sub-Saharan African controls (50 subjects each from
the Fon, Dendi, and Bariba populations, and 40 individuals from
the Berba population) [Pepe et al., 1999]. All controls were
apparently healthy individuals with no clinical cardiovascular or
connective tissue manifestations.
The study protocol was approved by the Ethics Committee of
Charles University-1st Faculty of Medicine. All homocystinuria
patients gave their informed consent via their primary care
physicians. Control subjects gave their written informed consent
during the course of sampling in the original study.
Genotyping
Genomic DNA was isolated from peripheral blood leukocytes or
cultured human fibroblasts by column extraction. Genotypes for 12
polymorphic CBS markers (for overview, see Fig. 1A) were determined
by fragment analysis of PCR products (c.1444_146717(16_21)
[known as 31 bp variable number of tandem repeats (VNTR)]),
amplification refractory mutations system PCR (ARMS-PCR)
(c.699C4T, c.833T4C, c.844_845ins68, and c.1080C4T),
PCR-RFLP (c.–3792G4A, c.699C4T, c.833T4C, c.1080C4T,
and c.543T4C [known as c.1985T4C]) and automated DNA
sequencing (c.13581161G4A, c.13581264A4G, c.1359–219C4T,
c.1359–134G4A, and c.1359–30C4T). The ARMS-PCR and
PCR-RFLP techniques were used interchangeably since they
yielded identical results. For detailed conditions and suppliers of
chemicals and instruments, see Supplementary Table S1 (available
online at http://www.interscience.wiley.com/jpages/1059-7794/
suppmat). The analysis of c.833T4C and c.844_845ins68 was
designed to permit unequivocal phase determination of these two
markers. The cDNA sequence numbering was based upon
GenBank reference sequence NM_000071.1 (the first adenosine
in the initiator ATG was designated as 11), genomic DNA
numbering was based upon GenBank reference sequence
NC_000021.7 and the numbering of the 31-bp VNTR was based
upon a literature report [Lievers et al., 2001].
Physical Haplotyping
A physical haplotyping method had to be developed in order to
permit haplotype determination in all study subjects because no
parental samples were available for phase determination. Since
PCR amplification of a 20-kb segment of the CBS gene proved
to be unreliable, PCR conditions to amplify a shorter 12.2-kb
FIGURE 1. Structureofthewild-typec.[833T;  ] and c.[833C;844_845ins68] CBS chromosomes. A:Thegenomicorganizationofthe
CBS gene, with exons depicted as numbered black boxes and the initiator ATG in exon 1 indicated by an upward-pointing arrow.
Markers genotyped in this study are denoted by downward-pointing arrows. B: Boxed uppercase letters represent the sequence of
wild-type exon 8.The lowercase sequence corresponds to £anking intronic regions.The thymidine residue at nucleotide position
833 is marked by an arrow. C:The sequence of the variant c.[833C; 844_845ins68] chromosome.The 68-bp insertion between nu-
cleotides 844 and 845 isbracketed. Boththemutationc.833Cinexon 8 andthewild-typethymidine 833 withinthe 68-bpinsertion
sequence areindicatedby arrows. Motifscorresponding toDNA polymerase a/bframeshift hotspotsandinvertedrepeats areshaded
andunderlined, respectively.
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and subsequently employed. Samples that yielded more than two
haplotypes (probably due to PCR jumping [Pa ¨a ¨bo et al., 1990])
and samples which failed in a 12.2-kb PCR amplification as
a consequence of poor template DNA quality, were amplified
in two overlapping 7.4-kb and 8.1-kb fragments spanning exon 5
to intron 13 and intron 9 to exon 17, respectively. Detailed
conditions for the PCR reactions are given in Supplementary Table
S1. The PCR products were gel-purified and cloned into
a bacterial vector using the TOPO
s XL PCR Cloning Kit
(Invitrogen; www.invitrogen.com, Carlsbad, CA) according to
the manufacturer’s instructions. Individual alleles were then
genotyped from plasmid DNA preparations as described above.
Throughout this work, the haplotypes have been described
using the following reference haplotype: NM_000071.1:
c.[–3792G4A; 699C4T; 833T4C; 844_845ins68; 1080C4T;
intron 12 cluster; c.1444_146717(16_21); 543T4C]. The intron
12 variants c.13581161G4A, c.13581264A4G, c.1359–219C4T,
c.1359–134G4A, and c.1359–30C4Twere clustered as follows:
a, [G; G; C; G; C]; b, [G; G; C; A; T]; g, [G; G; T; A; T], and d,
[ G ;A ;C ;G ;C ] .
Haplotyping in Controls
Genotypes for seven polymorphic markers were first examined
in all 390 control DNA samples, and HAPMAX (available at
www.uni-kiel.de/medinfo/mitarbeiter/krawczak/download/index.html)
analysis was performed to estimate the possible haplotype structure
of control chromosomes. Next, we searched manually for
homozygotes carrying the predicted haplotypes. In these samples,
genotyping was extended to the remaining five markers by
sequencing intron 12. If heterozygosity was observed for more
than one locus in the latter analysis, physical haplotyping was
employed. Several haplotypes predicted by HAPMAX were,
however, individually rare and were not found in the homozygous
state. Their existence was therefore also confirmed directly by the
physical haplotyping of selected samples.
Haplotyping in Patients Carrying Pathogenic
c.[833C;  ] Chromosomes
Genotypes for 12 polymorphic markers were determined in all
genomic DNA samples from homocystinuria patients. Of the 54
samples available, two did not amplify in any PCR and seven failed
in long-range PCR. The remaining 45 samples were amenable to
genotyping and physical haplotyping. CBS haplotypes were
determined either directly as a consequence of homozygosity for
at least 11 out of 12 markers, or by physical haplotyping.
GeographicalVariation in c.[833C;  ]
Chromosome Frequency
For selected countries, we were able to estimate not only the
population frequency of all homocystinuria-causing CBS alleles
combined, but also the CBS alleles bearing the c.833T4C
mutation. Since only a limited number of European countries
perform long-term neonatal screening for CBS deficiency (and
would thus have been able to provide reliable incidence data for
deriving these estimates), we simply used the population
prevalence of CBS deficiency to extrapolate allele frequencies.
Data were first collected on the number of all known
CBS-deficient patients and on their genotypes for each of the
countries involved using a combination of three approaches:
1) a questionnaire-based survey, with 11 laboratories approached
and eight replies received; 2) exploitation of the CBS Mutation
Database (www.uchsc.edu/cbs/cbsdata/cgidata.htm); and 3) litera-
ture searches. Owing to its much greater ethnic heterogeneity, no
attempt was made to perform this analysis in the United States.
Population sizes were taken from the United Nations World
Population Policies 2003 (www.un.org/esa/population/publications/
wpp2003/Publication_index.htm). For crude data, see Supplemen-
tary Table S2. Assuming Hardy-Weinberg equilibrium, the total
frequency of disease-causing CBS alleles was calculated as the
square root of the prevalence of CBS deficiency. Then, the
frequency of the c.[833C;  ] chromosomes was estimated by
multiplying this number by the proportion of c.[833C;  ]
chromosomes observed among patients. Finally, the combined
population frequency of disease-causing CBS chromosomes
in Europe was calculated from summary data on the numbers of
patients and the sum of respective population sizes of these
countries.
Statistical Analyses
Maximum likelihood estimates of haplotype frequencies were
obtained from genotype data of unrelated individuals using
the HAPMAX computer program. Confidence intervals for the
disease prevalence and allele frequency estimates were calculated
using the Wilson score method without continuity correction
[Newcombe, 1998].
RESULTS
HaplotypeAnalysis ofWild-Type CBS Chromosomes
First, we genotyped a set of seven polymorphic markers in all
390 control DNA samples from one European and four African
populations; the African populations were included so as to
provide the potential to acquire additional information on
identical-by-descent c.833C-bearing chromosomes. Subsequently,
five additional markers in intron 12 were genotyped in selected
samples in order to determine their CBS haplotypes. The
frequencies of most of the genotypes differed quite markedly
between Czech and African controls (for details see Table 1). The
frequencies of the c.1080C4T and c.543T4C variants were
substantially higher in the Czech population whereas the
frequency of the c.[833C; 844_845ins68] double mutation was
considerably lower than in Africans. Importantly, we did not
detect any c.833Tchromosomes carrying only the c.844_845ins68
lesion (i.e., c.[833T; 844_845ins68]), nor did we detect any
chromosomes bearing exclusively the c.833C mutation
(i.e., c.[833C;  ]). Thus, the c.844_845ins68 variant was in
absolute linkage disequilibrium with the c.833C mutation in all
population samples analyzed.
Next, haplotypes were constructed either from homozygous
genotypes or by performing physical haplotyping, employing all 12
polymorphic markers. Haplotypes involving intron 12 markers
c.13581161, c.13581264, c.1359–219, c.1359–134, and c.1359–30
could be divided into four different clusters, which we have termed
a [ G ;G ;C ;G ;C ] ,b [ G ;G ;C ;A ;T ] ,g [G; G; T; A; T], and d [G;
A; C; G; C], respectively.
Our study revealed a total of 29 and 18 different wild-type CBS
haplotypes, respectively, depending upon whether or not the
VNTR c.1444_146717(16_21) genotype was included (for details
see Table 2). Chromosomes carrying the c.[833C; 844_845ins68]
double mutation were found in both populations. European
chromosomes were found to harbor only two or four haplotypes,
respectively, depending upon whether or not VNTR heterogeneity
was considered, while the ancestral African chromosomes
displayed much greater haplotype variability. We attempted to
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generated by the HapMap Project (www.hapmap.org). Although
HapMap release 19/phase II from October 2005 contains an
array of CBS haplotypes, no direct comparison was possible owing
to the use of a completely different set of CBS SNPs by the
HapMap project.
TABLE 1. CBS MarkerAlleleFrequencies inControls
Marker
Allelefrequencies indi¡erent populations
Africancontrol populations
Czechcontrols Africancontrols Fon Dendi Berba Bariba
Number of chromosomes 400 380 100 100 80 100
c.^3792G4A 0.01 0.00 0.00 0.00 0.00 0.00
c.699C4T 0.32 0.20 0.1 7 0.24 0.15 0.24
c.833T4C 0.07 0.33 0.33 0.30 0.36 0.24
c.844___845ins68 0.07 0.33 0.33 0.30 0.36 0.24
c.1080C4T 0.42 0.00 0.00 0.00 0.01 0.00
c.1444___146717(16)
a 0.002 0.00 0.00 0.00 0.00 0.00
c.1444___146717(17) 0.07 0.22 0.29 0.15 0.24 0.21
c.1444___146717(18) 0.77 0.26 0.23 0.27 0.20 0.33
c.1444___146717(19) 0.11 0.19 0.12 0.16 0.15 0.13
c.1444___146717(21) 0.05 0.38 0.36 0.42 0.41 0.33
c.543T4C (known as c.1985T4C) 0.46 (C) 0.12 (T) 0.14 (T) 0.14 (T) 0.13 (T) 0.07 (T)
With the exception of theVNTR polymorphism, themarker frequencies are given as minor allele frequencies.ThecDNA sequence numberingis based
on GenBank reference sequence NM___000071.1 (the ¢rst adenosine in the initiatorATG is designated as 11), genomic DNA numbering is based on
GenBank reference sequence NC___000021.7 and the numbering of the 31-bp c.1444___146717(16_21) VNTR is based on a published report [Lievers
et al.,2001]. For an overview of polymorphisms in the CBS gene, see [Koz › ich andKraus,2001].
aThe length of the individualVNTR motifs is invariably 31bp; however,di¡erent single-nucleotide substitutions may bepresent within the repeat units,
as described previously by Lievers et al. [2001].
TABLE 2. CBS HaplotypesObservedinControlChromosomes
Haplotype
a
Population
b
Detectionmethod X, numberofc.1444___146717(16___21) VNTRrepeats Czech African
c.[833T;-] haplotypes
[G;T;T;-;C;a;X ;C ] P 2 1 ^ 1
[G;C ;T ;-;C ;b;X ; C ] H 1 9 ^ 1
[G;T;T;-;C;b;X ;C ] H 1 9 ^ 1
[G;T;T;-;C;g;X ;C ] H 1 9 1 ^
[G;T;T; -;C; g;X ;T ] H 1 8 11
same as above H 19 11
[G ;C ;T ;-;C ;d;X ;C ] H 1 8 11
same as above H 21 11
[G;C;T;-;C;d;X ;T ] H 1 7 11
same as above H 18 11
same as above H 19 11
same as above H 21 11
[G;T;T;-;C;d;X ;T ] H 1 7 11
same as above H 18 11
same as above H 21 11
[G;C;T; -;T; d;X ;C ] H 1 8 1 ^
[G;T;T;-;T;d;X ;C ] P 1 6 1 ^
same as above H 18 1 ^
[G;C;T;-;T;d;X ;T ] H 1 8 1 ^
c.[833C;844___845ins68] haplotypes
[G ;C ;C ;ins ;C ;a;X ;C ] P 1 8 ^ 1
[G ;C ;C ;ins ;C ;b;X ;T ] H 1 7 11
same as above H 18 11
same as above H 21 11
[A;C ;C ;ins ;C ;b;X ;T ] P 1 7 1 ^
[G;C;C; ins;T; b;X ;T ] P 1 7 ^ 1
[G;T;C; ins;C; b;X ;T ] H 1 7 ^ 1
[G ;C ;C ;ins ;C ;d;X ;C ] P 2 1 ^ 1
[G ;C ;C ;ins ;C ;d;X ;T ] H 1 7 ^ 1
same as above H 19 ^ 1
Haplotypes were determinedeither by homozygosity of at least11markers (detection method H) or by physical haplotyping (detection method P).
aHaplotypes are described in relation to the reference CBS haplotype- NM___000071.1: c.[-3792G4A; 699C4T; 833T4C; 844___845ins68; 1080C4T;
intron 12 cluster; c.1444___146717(16___21); *543T4C], for details see Patients and Methods. The intron 12 variants c.13581161G4A, c.13581
264A4G, c.1359-219C4T, c.1359-134G4A and c.1359-30C4Twereclusteredasfollows: a, [G;G;C;G;C]; b,[G ;G ;C ;A ;T];g,[G ;G ;T ;A ;T]a n dd,[G ;A ;C ;G ;C].
b1, haplotype observed in the studied population sample; ^, haplotype not detected in the studied population sample.
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of Homocystinuric Chromosomes
The population frequency of patients with clinically ascertained
and biochemically confirmed CBS deficiency varied considerably
between countries, averaging  1 out of 1,500,000 inhabitants
in Europe and yielding an estimated population frequency
of pathogenic CBS alleles of 0.82   10
–3. The population
frequency of the c.833C allele, as estimated from the number of
homocystinuria patients carrying at least one c.[833C;  ] chromosome,
varied by an order of magnitude between the 13 European
countries, with the highest prevalence being observed in northern
Europe. The calculated frequency of this allele in Europe (qc.833C
F 0.18   10
–3) was  20-fold lower than actually observed in
healthy controls—mostly unselected newborns—from several
European countries (qc.833C F 3.3   10
–3) (see Table 3). This
discrepancy is suggestive either of the decreased antenatal viability
of c.[833C;  ] homozygotes, the premature death of patients, or,
rather more plausibly, an ascertainment bias with respect to
patients having a clinically less apparent and milder pyridoxine-
responsive form of the disease due to c.[833C;  ] homozygosity.
Haplotypes of c.[833C;  ] chromosomes and their frequencies
were determined by a combination of physical haplotyping and
statistical analysis. Physical haplotyping of two-thirds of the
available mutant chromosomes revealed three distinct and
unrelated haplotypes ([G; C; C;  ;C ;d; 21; T], [G; C; C;  ;
T; d; 18; C], and [G; T; C;  ;C ;g; 19; C]) that differ from their
respective wild-type counterparts only by the substitution of
c.833C for c.833T. To reveal additional haplotypes that might
have been present in samples that were not amenable to physical
haplotyping, a maximum likelihood analysis was performed on the
genotypes of 52 homocystinuric patients (representative of 69
c.[833C;  ] chromosomes). As is evident from Supplementary
Table S3, HAPMAX revealed the same three c.[833C;  ]
haplotypes as before, with frequency estimates that were virtually
identical to those determined by physical haplotyping. Interestingly,
the haplotype containing the d cluster of intron 12 variants has
been previously observed in patients of German origin (designated
the ‘‘A1 haplotype’’ in Linnebank et al. [2001b]). We were unable to
detect any c.833C-bearing haplotype containing cluster b of intron
12 variants (designated the ‘‘B1 haplotype’’ in the Linnebank et al.
[2001b] study), and with hindsight this may have been due to
different although partially overlapping sets of German patients
having been included in the original and the present study.
The distribution of different pathogenic c.[833C;  ] haplotypes
varied between different European countries (see Fig. 2), reflecting
the complex population history of the mutant CBS chromosomes.
It is important to stress that we did not observe any heterogeneity
in the number of VNTR repeats for any of the mutant haplotypes,
consistent with a rather recent occurrence of all mutant c.[833C;  ]
chromosomes. The [G; T; C;  ;C ;g; 19; C] haplotype was present
in 8 out of 9 European countries tested, suggesting that it might be
the most ancient one. By contrast, [G; C; C;  ;T ;d; 18; C] was
restricted to the northern/central part of Europe, while [G; C;
C;  ;C ;d; 21; T] was confined to Italy. This variable geographical
distribution suggests either different migration patterns or the more
recent occurrence of the latter two mutant haplotypes.
Search for Mutational Hotspots
in theVicinityof c.833T
There is no obvious reason to suppose that thymidine in position
c.833 is hypermutable per se. Moreover, the immediate vicinity of the
nucleotide c.833 does not contain any repetitive sequence elements
that could have templated the c.833T4C transition and hence
accounted for its independent occurrence on distinct haplotypes.
However, analysis of the regions flanking the adjacent
nucleotide c.844, at which the 68-bp duplication occurs, revealed
the presence of two sequence elements with mutational potential
(see Fig. 1C). The first, at position c.834_839, was a 50-TGGGGT-
30 sequence that matches the DNA polymerase a/b frameshift
hotspot consensus sequence 50-TG(G/A)(A/G)(G/A)(C/T)-30
TABLE 3. PopulationFrequency ofPathogenic CBS Chromosomes
Country
Frequencycalculatedfromnumberof
diagnosedpatientswith homocystinuria
a
Frequency determinedin
healthycontrols
b
All pathogenic CBS chromosomes c.[833C;  ] chromosomes c.[833C;  ] chromosomes
Czech Republic 1.1 (0.86^1.5) 0.30 (0.23^0.40) 2.0 (0.83; 4.6)
Denmark 1.6 (1.2^2.1) 0.81 (0.62^1.0) 7.0 (3.4^14.6)
France 0.52 (0.40^0.66) 0.048 (0.038^0.062)
Germany 0.76 (0.66^0.88) 0.21 (0.19^0.25) 7.5 (2.6^22.0)
Hungary 1.1 (0.83^1.5) 0.046 (0.035^0.061)
Ireland 3.3 (2.8^3.8) 0.12 (0.099^0.13)
Italy 0.58 (0.46^0.72) 0.14 (0.11^0.17)
Norway 1.5 (1.1^2.0) 0.15 (0.11^0.20) 3.1 (1.5^6.4)
Netherlands 1.5 (1.2^1.7) 0.80 (0.68^0.94) 2.0 (0.5^7.3)
Poland 0.66 (0.52^0.84) 0.020 (0.015^0.025)
Slovakia 1.2 (0.87^1.7) 0.076 (0.054^0.11)
Spain 0.58 (0.45^0.76) 0 (0.0^0.0)
UnitedKingdom 0.49 (0.38^0.63) 0.14 (0.11^0.18)
Europe 0.82 (0.77^0.87) 0.18 (0.17^0.19) 3.3 (2.2^5.0)
Australia^New SouthWales 2.4 (2.1^2.9) 0.31 (0.26^0.36) 0 (0.0^4.0)
Japan 0.58 (0.50^0.67) 0.013 (0.012^0.016)
Frequencies are given as number per1,000 chromosomes (i.e.,   10
^3).
aRaw data for calculating allele frequencies are given in Supplementary Table S2; the calculations are described in detail in the Patients and
Methods section.
bPopulation frequencies of the c.[833C;  ] chromosome were calculated from original data published for Czech [Sokolova ¤ et al.,2001], Danish [Gaustadnes
et al., 1999], German [Linnebank et al., 2001a], Norwegian [Refsum et al., 2004], and Australian newborns (personal communication by B. Wilcken;
n 5 1,160 consecutivenewborns), andforDutch healthycontrols [Gri⁄oenet al.,2005].The 95% con¢denceintervals aregiveninparentheses.
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ATCCA/TGGAT, flanking the 68-bp insertion site that appears
to be capable of forming an imperfect hairpin loop that could have
mediated the exclusion of the inserted sequence while still preserving
the pathogenic c.833C mutation on the same chromosome.
In summary, analysis of mutational hotspots and the haplotypes
of c.833C-bearing chromosomes suggests a complex history
for their generation, with neutral c.[833C; 844_845ins68] chromo-
somes having potentially templated the generation of mutant
c.[833C;  ] chromosomes via several mechanisms (see Discussion).
DISCUSSION
In this study, we have presented evidence to support the view
that the most common homocystinuria mutation c.833T4C
(p.I278T) occurred both repeatedly and independently during the
recent history of European populations. This assertion is based
mainly upon the observation of three unrelated CBS haplotypes
containing solely the pathogenic c.833T4C substitution. Since
the recurrence of the c.833T4C mutation cannot be explained
by any known mutational hotspot in the vicinity of c.833T, a
different mutational mechanism should be considered.
The high prevalence of the neutral c.[833C; 844_845ins68]
chromosomes in Europe prompted us to propose that these
nonpathogenic chromosomes may have templated the repeated
generation of pathogenic c.[833C;  ] chromosomes. Different
mutational mechanisms such as meiotic recombination, loop
formation with subsequent excision, or gene conversion could
have been responsible for recurrently converting wild-type
chromosomes into pathogenic c.[833C;  ] ones, using neutral
c.[833C; 844_845ins68] chromosomes as templates.
Meiotic recombination as a mechanism for repeated mutagen-
esis appears unlikely owing to the close physical proximity of
nucleotides 833 and 844. A meiotic event should have generated
a c.844_845ins68 chromosome lacking the c.833C mutation. In 15
published studies containing data on the phase of the c.833C
mutation and the c.844_845ins68 variant, a total of 10,074 CBS
chromosomes were genotyped and 1,721 c.[833C; 844_845ins68]
chromosomes were found. However, not a single c.833T
chromosome carrying only the c.844_845ins68 variant (i.e.,
c.[833T; 844_845ins68]) has been reported, indicating complete
linkage disequilibrium of the c.844_845ins68 variant with c.833C
[Aras et al., 2000; Dilley et al., 2001; Dutta et al., 2005; Fillon-
Emery et al., 2004; Franco et al., 1998a, 1998b; Giusti et al., 1999;
Griffioen et al., 2005; Janos ˇı ´kova ´ et al., 2003; Orenda ´c ˇ et al.,
1999; Pepe et al., 1999; Sokolova ´ et al., 2001; Tsai et al., 2000,
1999; Zoossmann-Diskin et al., 2004].
The inverted repeat flanking the 68-bp insertion could, however,
have templated the recurrent conversion of neutral c.[833C;
844_845ins68] chromosomes into pathogenic c.[833C; -] chromo-
somes via loop formation and excision. To explore this second
hypothesis, we compared both the pathogenic and neutral
haplotypes harboring c.833C. The two major European pathogenic
haplotypes, i.e., [G; T; C;  ;C ;g; 19; C] and [G; C; C;  ;T ;d;1 8 ;
C], are unrelated to any of the neutral c.[833C; 844_845ins68]
haplotypes. Therefore, their emergence by loop excision from any
FIGURE 2. Distribution of c.[833C;  ] haplotypes in Europe.Three di¡erent pathogenic haplotypes ([G; C; C;  ;C ;d;2 1 ;T],[G ;C ;
C;  ;T ;d;1 8;C],and[G;T ;C; ;C ;g;19; C]) were observed among European homocystinuria patients. Haplotypes are described
in relation to the reference CBS haplotype, for details see Patients and Methods.The number of chromosomes is proportional to the
size of the column in each country, normalized by the black square representing one allele; it may also be found in Supplementary
Table S3. [Color ¢gurecan beviewedin theonlineissue,whichis available at www.interscience.wiley.com.]
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would appear to be inherently unlikely. By contrast, the rare
pathogenic haplotype [G; C; C;  ;C ;d; 21; T] differs from the
nonpathogenic haplotype [G; C; C; ins; C; d; 17/19; T] only by
virtue of the absence of the insertion at position c.844_845 and
by the number of VNTR repeats. A complex, albeit still feasible,
mechanism involving both loop excision and DNA polymerase
slippage in the VNTR locus could have led to the formation of
pathogenic [G; C; C;  ;C ;d; 21; T] chromosomes. However, the
putatively templating chromosome was only found in sub-Saharan
African controls while the corresponding pathogenic haplotype
was only present in Italy.
The third hypothesis invoking gene conversion, however, is
favored by the observation that the c.833T4C mutation abuts the
DNA polymerase a/b frameshift hotspot consensus sequence
50-TG(G/A)(A/G)(G/A)(C/T)-30, known to be involved in strand
breakage. Moreover, all three mutant c.[833C;  ] haplotypes have
a wild-type c.[833T;  ] counterpart, consistent with their
emergence via gene conversion. In addition, the VNTR hetero-
geneity characteristic of the non-pathogenic c.[833C;
844_845ins68] chromosomes is lacking on mutant c.[833C;  ]
chromosomes. This is consistent with the view that the neutral
c.[833C; 844_845ins68] chromosomes preceded the mutant
c.[833C;  ] chromosomes in evolutionary time. We therefore
propose that, in individuals heterozygous for the wild-type c.[833T;  ]
and c.[833C; 844_845ins68] chromosomes, a double-strand break
of the c.[833T;  ] chromosome at the DNA polymerase a/b
frameshift hotspot consensus sequence may have occurred.
Subsequent strand invasion, formation of Holliday junctions and
excision repair of an incomplete loop could then have formed the
three mutant c.[833C,  ] haplotypes (the proposed mechanism is
depicted in Fig. 3). Gene conversion has been implicated in a
number of different human diseases [Patrinos and Grosveld, 2003]
and we propose that homocystinuria due to the c.833T4C
transition may be yet another example.
A wide variability in the frequency of pathogenic c.[833C;  ]
chromosomes obtained from known homocystinuria patients in
different populations is evident; northern Europe has the highest
frequency while Japan has the lowest and the Iberian peninsula
appears to be entirely devoid of c.[833C;  ] chromosomes. If
the nonpathogenic c.[833C; 844_845ins68] chromosomes did
indeed template the creation of mutant c.[833C;  ] chromosomes
by gene conversion, one would expect that the population
frequency of these mutant chromosomes would be positively
correlated with the prevalence of the nonpathogenic ones.
Consistent with this prediction, the low prevalence of c.[833C;
844_845ins68] chromosomes in Asia is indeed associated with the
low prevalence, or even absence, of the c.[833C;  ] chromosomes
among Japanese [Katsushima et al., 2006] and Korean [Lee et al.,
2005] homocystinuria patients, whereas a much higher prevalence
of both the pathogenic and neutral chromosomes is apparent in
Europe. Unfortunately, the assessment of this correlation could not
be extended to sub-Saharan Africa due to a lack of reliable data on
the frequency of homocystinuria in countries from this region, and
because the control sample size in our study was probably too small
to detect c.[833C;  ]1[833T;  ] heterozygotes.
It is at present unclear how much of the variability in the
prevalence of the pathogenic c.[833C;  ] chromosome can be
attributed to the above mentioned mutagenic mechanisms as
opposed to random drift, migration, and selection. It is also unclear
to what extent this variability is due to the negative clinical
ascertainment bias of mildly affected patients carrying the
pathogenic c.[833C;  ] chromosome (homozygotes and compound
heterozygotes for this allelic variant manifest a pyridoxine-
responsive homocystinuria with a milder clinical phenotype and
such individuals may have not invariably been diagnosed as having
FIGURE 3. Gene conversion as a possible mechanism for recur-
rent mutation. A hypothetical mechanism by which the
c.[833C; 844_845ins68] chromosomes could serve as template
for the generation of the pathogenic c.[833C;  ] chromosomes.
The upper two strands represent the wild-type c.[833T;  ]c h r o -
mosomes and the two bottom strands represent a variant wild-
type c.[833C; 844_845ins68] chromosome. Intron 7 is shown
as a black line, exon 8 is a gray line, and the insertion of 68 bp
isshowningreen.Thepathogenicmutationc.833Cisshownasa
red square. In step A, a double strand break occurs at the DNA
polymerase a/b frameshift hotspot followed by 50-30 exonu-
clease activity on the c.[833T;  ] chromosome in step B. Subse-
quent strand invasion occurs in step C and results in the
formationofaHollidayjunctioninstepD. InstepE, strandrepair
leads to the occurrence of a loop that is subsequently cleaved,
generating the neutral c.[833C; 844_845ins68] and pathogenic
c.[833C;  ] chromosomes duringgametogenesis (stepF).
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number of reports of c.[833C;  ]1[833C;  ] homozygotes and of
c.[833C;  ]1[other] compound heterozygotes who suffer from an
unusual form of the disease, manifesting only a thrombotic
diathesis without affecting connective tissue or the central nervous
system [Gaustadnes et al., 2000, 2002; Linnebank et al., 2003;
Maclean et al., 2002].
The phenotypic expression of the c.833T4C mutation in
heterozygotes is essentially unknown [Guttormsen et al., 2001;
Sperandeo et al., 1996a]. It is also unclear whether females
heterozygous for the pathogenic c.[833C;  ] chromosomes may
have had a more favorable pregnancy outcome (reduced bleeding
potential)—as proposed in cases of thrombophilia [Gopel et al.,
2001; Lindqvist et al., 1998]—under the as yet unproven
assumption that heterozygotes for CBS deficiency are in general
more prone to thromboembolism [Mudd et al., 1981; Swift and
Morrell, 1982]. It remains possible that the general living
conditions could have been more disadvantageous to hetero-
zygotes in Africa than in Europe, so that the question of whether
or not the high frequency of c.833C in Europe may have been in
part due to selection remains open.
Our study has revealed a considerable haplotype diversity of
wild-type CBS chromosomes in the studied European and African
populations. Were the VNTR polymorphism also to be considered,
the number of haplotypes common to both populations would
be 14. Czech controls carried six population-specific haplotypes,
whereas controls from Africa exhibited nine unique haplotypes.
These findings are consistent with the more recent emergence of
European populations as compared to the ancestral populations
originating in Africa.
In conclusion, our study has demonstrated significant worldwide
differences in the frequency of disease-causing c.[833C;  ]
chromosomes, which are associated with three unrelated CBS
haplotypes in populations of predominantly European origin. We
propose that a complex evolutionary process was responsible for
the formation of these haplotypes and that the common neutral
c.[833C; 844_845ins68] chromosomes might have been a source
of pathogenic c.[833C;  ] chromosomes by mechanisms that
probably involved gene conversion.
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